# Comparison Between Carbapenems and Noncarbapenem Beta-lactam Antibiotics in Septic Burn Patients

> **NCT07096310** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Ain Shams University** · enrollment: 400 (estimated)

## Conditions studied

- Sepsis

## Interventions

- **DRUG:** Meropenem I.V. 2g as a 3 hour infusion every 8 hours
- **DRUG:** Tazocin (pipercillin/tazobactam)

## Key facts

- **NCT ID:** NCT07096310
- **Lead sponsor:** Ain Shams University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-01-01
- **Primary completion:** 2026-01-15
- **Final completion:** 2026-03-01
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2025-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07096310

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07096310, "Comparison Between Carbapenems and Noncarbapenem Beta-lactam Antibiotics in Septic Burn Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07096310. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*